Based on the above, the detection of NALCN promoter methylation in NSCLC tumor tissue provides important prognostic information for NSCLC patients, while we strongly believe that NALCN promoter methylation in plasma ctDNA should be further evaluated and validated as a non-invasive circulating tumor biomarker in a large and well-defined patient cohort. Here, NALCN is linked to neoplasm.